University of Nottingham
The clinical interests of the Division are in the treatment of acute stroke, enhancing recovery and preventing recurrence; the following multicentre trials are coordinated by the Stroke Trials Unit: ultra-acute lowering of blood pressure before hospitalisation (RIGHT trial); hyperacute cooling/hypothermia (EU FP-7 trial); hyperacute tranexamic acid for primary intracerebral haemorrhage (HTA TICH-2 trial); acute lowering of BP in hospital (MRC ENOS trial of glyceryl trinitrate); acute intensive antiplatelets for preventing early recurrence (BHF-HTA TARDIS trial); prevention of post stroke cognitive impairment (TSA-AS PODCAST trial); chronic mobilisation of endogenous stem cells (RfPB STEMS-3 trial of granulocyte colony stimulating factor); the translational studies aim to identify a series of novel therapeutic targets that can subsequently be employed in clinical settings to prevent and/or reverse ischaemic injury-mediated breakdown of the blood-brain barrier and the ensuing formation of brain oedema which accounts for the majority of deaths within the first week after an ischaemic stroke; in this regard, the currently ongoing projects focus on pro-inflammatory cytokines, notably TNF-alpha and Interleukin-1beta; NADPH oxidase enzyme system and oxidative stress; matrix metalloproteinases, Plasminogen-plasmin system components; hypothermia.
|Qualification||Study mode||Start month||Fee||Course duration|
|Campus name||Town||Postcode||Region||Main campus||Campus||Partner|
|Queen's Medical Centre||Nottingham||NG7 2HA||East Midlands|
Get in touch
Remember to mention TARGETpostgrad when contacting universities.
+44 (0) 115 951 5559